Your session is about to expire
← Back to Search
Pembrolizumab + Lenvatinib for Neuroendocrine Prostate Cancer(PLANE-PC Trial)
PLANE-PC Trial Summary
This trial will use a combination of lenvatinib and pembrolizumab to treat eligible patients. Each cycle is 21 days long, and the therapy will continue until the patient's condition either improves or worsens, they can't tolerate the treatment, or they and their physician decides to stop. Up to 35 cycles may be administered.
- Neuroendocrine Tumors
- Prostate Cancer
PLANE-PC Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
PLANE-PC Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
PLANE-PC Trial Design
Find a Location
Who is running the clinical trial?
- Group 1: Study Treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other research initiatives have been undertaken using Lenvatinib?
"Presently, 1032 clinical trials worldwide are studying the effects of Lenvatinib. Of those active studies, 134 of them are in their final Phase 3 stage. Primarily based in Sacramento, California; 37061 locations have opened up testing sites for this particular medication."
What is the intended outcome of this trial?
"This two-year trial seeks to assess the Radiologic Progression Free Survival (rPFS) of soft tissue lesions. Secondary measurements such as Overall Survival, Objective Response Rate and Frequency/Severity of Adverse Events will be taken in accordance with Common Terminology Criteria for Adverse Events version 5.0."
To what extent is this research currently enrolling participants?
"The sponsor, Merck Sharp & Dohme LLC, must recruit 50 patients that meet the pre-defined inclusion criteria in order to initiate this trial. The clinical sites include University of Michigan Health System located in Ann Arbor and Winship Cancer Instituted from Emory University based out of Atlanta."
Are applications for this experiment being accepted currently?
"According to the information provided by clinicaltrials.gov, this investigation is actively searching for research subjects. The trial was first made available on May 25th 2021 and has been recently revised on October 26th 2022."
What kind of adverse reactions have been observed in people taking Lenvatinib?
"Lenvatinib's safety has been characterized to some extent, thus a score of 2 was assigned. This is because there are Phase 2 clinical trial results for this medication but no established evidence supporting its efficacy."
What medical goals is Lenvatinib typically utilized to achieve?
"Lenvatinib is typically employed to battle malignant tumours. It can also be used to help individuals with unresectable melanoma, microsatellite instability high and those that have regressed after chemotherapy therapy."
Share this study with friends